Try our mobile app

Switch to company model in classical logic    *

General information

Country: CANADA

Sector: Biotechnology

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company`s lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Website: inmedpharma.com



Growth: Bad revenue growth rate 0.0%, there is slowdown compared to average historical growth rates 16.7%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -1 800.0%. Gross margin is high, +48.5%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 50% of quarters (showing a gain of -$1.98 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -3 828.6% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 5.2% higher than minimum and 99.7% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -85.7x by EV / Sales multiple

Insiders: For the last 3 months insiders bought company shares on $0.0 mln (5.603% of cap.)

Key Financials (Download financials)

Ticker: INM
Share price, USD:  (-8.3%)0.242
year average price 0.6595  


year start price 1.2300 2023-05-06

max close price 1.4000 2023-05-22

min close price 0.2300 2024-04-26

current price 0.2420 2024-05-04
Common stocks: 1 411 840

Dividend Yield:  0.0%
Last revenue growth (y/y):  > 200.0%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  16.7%
Historical growth of EBITDA:  ---
EV / Sales: -4.6x
Margin (EBITDA LTM / Revenue): -1 800.0%
Fundamental value created in LTM:
Market Cap ($m): 0
Net Debt ($m): -5
EV (Enterprise Value): -5
Price to Book: 0.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2023-10-25InvestorPlace

Why Is InMed Pharmaceuticals (INM) Stock Down 25% Today?

2023-10-24InvestorPlace

Why Is InMed (INM) Stock Up 110% Today?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol INM INM INM INM INM INM
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-13 2023-11-14 2023-09-29 2023-05-15 2023-02-17 2022-11-14
acceptedDate 2024-02-13 17:05:59 2023-11-13 17:34:53 2023-09-29 11:43:01 2023-05-15 11:46:28 2023-02-17 16:06:06 2022-11-14 06:22:02
calendarYear 2024.000 2024.000 2023.000 2023.000 2023.000 2023.000
period Q2 Q1 Q4 Q3 Q2 Q1
revenue 1M 2M 2M 1M 469 783 320 788
costOfRevenue 916 058 2M 740 685 841 414 338 620 811 806
grossProfit 324 142 21 242 2M 192 511 131 163 -491 018
grossProfitRatio 0.261 0.013 0.680 0.186 0.279 -1.531
researchAndDevelopmentExpenses 609 791 1M 623 744 878 303 851 356 1M
generalAndAdministrativeExpenses 1M 1M 1M 1M 1M 2M
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 1M 1M 1M 1M 1M 2M
otherExpenses -170 469 -92 930 -148 786 50 689 49 049 49 048
operatingExpenses 2M 3M 2M 2M 2M 3M
costAndExpenses 3M 4M 3M 3M 3M 4M
interestIncome 166 760 136 043 148 559 155 497 115 797 72 587
interestExpense 0 0 102M -102M -156 271 72 587
depreciationAndAmortization 152 608 54 832 150 972 149 161 49 049 148 508
ebitda -2M -3M -396 402 -2M -2M -3M
ebitdaratio -1.300 -1.488 -0.172 -1.932 -4.694 -10.081
operatingIncome -1 650M -3M -8 169M -2M -2M -3M
operatingIncomeRatio -1330.114 -1.521 -3534.628 -2.076 -4.799 -10.544
totalOtherIncomeExpensesNet 59 896 32 754 31 112 150 031 156 271 -120 995
incomeBeforeTax -1M -3M -336 591 -2M -2M -4M
incomeBeforeTaxRatio -1.192 -1.501 -0.146 -1.931 -4.466 -10.921
incomeTaxExpense -226 656 0 1800.000 1500.000 3000.000 6800.000
netIncome -1M -3M -338 391 -2M -2M -4M
netIncomeRatio -1.192 -1.501 -0.146 -1.932 -4.472 -10.942
eps -0.190 -0.760 -0.100 -0.600 -0.910 -4.060
epsdiluted -0.190 -0.760 -0.100 -0.600 -0.910 -4.060
weightedAverageShsOut 8M 3M 3M 3M 2M 865 619
weightedAverageShsOutDil 8M 3M 3M 3M 2M 865 619
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol INM INM INM INM INM INM
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-13 2023-11-14 2023-09-29 2023-05-15 2023-02-17 2022-11-14
acceptedDate 2024-02-13 17:05:59 2023-11-13 17:34:53 2023-09-29 11:43:01 2023-05-15 11:46:28 2023-02-17 16:06:06 2022-11-14 06:22:02
calendarYear 2024.000 2024.000 2023.000 2023.000 2023.000 2023.000
period Q2 Q1 Q4 Q3 Q2 Q1
cashAndCashEquivalents 10M 7M 9M 10M 11M 9M
shortTermInvestments 44M 43M 44M 43M 43 053 42 125
cashAndShortTermInvestments 10M 7M 9M 10M 11M 9M
netReceivables 372 870 165 850 260 399 170 299 81 647 15 169
inventory 744 839 1M 2M 1M 2M 2M
otherCurrentAssets 1M 215 015 498 033 695 203 826 931 356 665
totalCurrentAssets 12M 8M 11M 12M 14M 12M
propertyPlantEquipmentNet 1M 615 055 723 426 753 241 703 922 802 369
goodwill 0 0 0 0 0 0
intangibleAssets 2M 2M 2M 2M 2M 2M
goodwillAndIntangibleAssets 2M 2M 2M 2M 2M 2M
longTermInvestments 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0
otherNonCurrentAssets 100 000 101 790 104 908 147 489 171 130 171 130
totalNonCurrentAssets 3M 3M 3M 3M 3M 3M
otherAssets 0 -0.000 0 0 0 0
totalAssets 15M 11M 14M 15M 17M 15M
accountPayables 306 455 379 866 544 179 737 501 2M 1M
shortTermDebt 364 190 292 998 375 713 423 574 414 307 404 163
taxPayables 0 0 0 0 0 0
deferredRevenue -1 679M -1 339M -2 000M 0 0 15 700
otherCurrentLiabilities 1 680M 1 339M 2 001M 1M 16 171 2M
totalCurrentLiabilities 2M 1M 2M 2M 2M 3M
longTermDebt 802 784 0 15 994 72 794 183 902 294 337
deferredRevenueNonCurrent 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 0 0 0 -1M
totalNonCurrentLiabilities 802 784 0 15 994 72 794 183 902 294 337
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 1M 292 998 391 707 496 368 598 209 698 500
totalLiabilities 2M 1M 2M 2M 3M 4M
preferredStock 0 0 0 0 0 0
commonStock 80M 78M 78M 78M 75M 73M
retainedEarnings -105M -104M -101M -101M -99M -97M
accumulatedOtherComprehensiveIncomeLoss 128 569 128 569 128 569 128 569 128 569 128 569
othertotalStockholdersEquity 38M 36M 36M 36M 38M 35M
totalStockholdersEquity 13M 10M 12M 12M 14M 11M
totalEquity 13M 10M 12M 12M 14M 11M
totalLiabilitiesAndStockholdersEquity 15M 11M 14M 15M 17M 15M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 15M 11M 14M 15M 17M 15M
totalInvestments 44M 43M 44M 43M 43 053 42 125
totalDebt 1M 292 998 391 707 496 368 598 209 698 500
netDebt -8M -6M -9M -9M -11M -9M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol INM INM INM INM INM INM
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-13 2023-11-14 2023-09-29 2023-05-15 2023-02-17 2022-11-14
acceptedDate 2024-02-13 17:05:59 2023-11-13 17:34:53 2023-09-29 11:43:01 2023-05-15 11:46:28 2023-02-17 16:06:06 2022-11-14 06:22:02
calendarYear 2024.000 2024.000 2023.000 2023.000 2023.000 2023.000
period Q2 Q1 Q4 Q3 Q2 Q1
netIncome -1M -3M -338 391 -2M -2M -4M
depreciationAndAmortization 152 608 149 364 150 972 149 161 147 356 148 508
deferredIncomeTax 169 434 94 948 8M 0 0 0
stockBasedCompensation 18 264 25 191 40 480 50 357 70 638 116 680
changeInWorkingCapital -709 773 93 650 -263 484 141 803 -955 064 510 924
accountsReceivables -207 019 94 549 -111 790 -88 652 -91 563 72 858
inventory 217 784 390 329 -18 590 283 575 165 017 135 559
accountsPayables -749 194 -375 057 -912 235 0 0 0
otherWorkingCapital 28 656 -16 171 779 131 -53 120 -1M 302 507
otherNonCashItems -481.000 -538.000 -8M -3.000 125 061 478 545
netCashProvidedByOperatingActivities -2M -2M -657 934 -2M -3M -2M
investmentsInPropertyPlantAndEquipment -9219.669 0 -33 606 -128 198 0 0
acquisitionsNet 0 0 0 0 0 0
purchasesOfInvestments 163.659 -21 317 0 0 0 0
salesMaturitiesOfInvestments -163.659 21 317 0 0 0 0
otherInvestingActivites -71.331 0 0 0 0 0
netCashUsedForInvestingActivites -9291.000 0 -33 606 -128 198 -500 000 0
debtRepayment 0 0 0 0 0 0
commonStockIssued 5M 0 -12M 174.000 6M 6M
commonStockRepurchased 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites 0 0 12M -63 871 -684 650 -571 261
netCashUsedProvidedByFinancingActivities 5M 0 -654.000 -63 697 5M 5M
effectOfForexChangesOnCash -413M 0 3.000 0 0 0
netChangeInCash 3M -2M -691 540 -2M 2M 3M
cashAtEndOfPeriod 10M 7M 9M 10M 11M 9M
cashAtBeginningOfPeriod 7M 9M 10M 11M 9M 6M
operatingCashFlow -2M -2M -657 934 -2M -3M -2M
capitalExpenditure -9219.669 0 -33 606 -128 198 0 0
freeCashFlow -2M -2M -691 540 -2M -3M -2M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2022 q2
2022-09-23 ET (fiscal 2022 q4)
2021 q4
2022-02-15 ET (fiscal 2022 q2)

Press-releases

Show financial reports only

2024-02-13 22:41 ET
InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update
2024-02-09 13:00 ET
InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer
2024-01-26 13:40 ET
InMed Pharmaceuticals Has Multiple Milestones Coming Up In 2024, With A Focus On Three Conditions With An Unmet Need
2024-01-18 21:41 ET
InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET
2024-01-16 13:00 ET
InMed Pharmaceuticals Provides Business Update and Milestones for 2024
2023-12-19 23:03 ET
InMed Announces Results of 2023 Annual General Meeting
2023-12-12 14:25 ET
InMed’s (NASDAQ: INM) Latest Research Demonstrates Potential In Treating Alzheimer’s with a Rare Cannabinoid Analog
2023-11-29 13:00 ET
InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular Degeneration
2023-11-14 13:04 ET
InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update
2023-11-02 12:00 ET
InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023
2023-10-26 23:15 ET
InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules
2023-10-24 20:38 ET
InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules
2023-10-24 11:30 ET
InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies
2023-09-29 17:21 ET
InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update
2023-09-22 22:15 ET
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance
2023-09-07 12:30 ET
InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference
2023-07-21 11:30 ET
InMed to Participate in Fireside Chat with Water Tower Research on July 25, 2023 at 2pm ET
2023-07-20 11:30 ET
InMed Provides Update on BayMedica Rare Cannabinoid Business
2023-06-22 11:30 ET
InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa
2023-06-01 11:30 ET
InMed's Neurodegenerative Disease Study Presented at Canadian Neuroscience Meeting
2023-05-24 22:51 ET
InMed to Participate in Upcoming Virtual Investor Events
2023-05-18 21:00 ET
InMed to Participate in Fireside Chat with Water Tower Research on May 23, 2023 at 1pm ET
2023-05-15 16:33 ET
InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update
2023-03-28 11:30 ET
InMed Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa
2023-03-13 11:30 ET
InMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cannabinoids in Skin Conditions
2023-03-06 23:00 ET
InMed to Participate in Upcoming Investor Events
2023-02-17 22:00 ET
InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update
2023-02-10 02:40 ET
InMed Submits Form 12b-25
2023-01-10 12:30 ET
InMed Provides Business Update and Milestones for 2023
2022-12-15 23:17 ET
InMed Announces Results of 2022 Annual General Meeting
2022-12-12 23:47 ET
InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor
2022-11-21 22:00 ET
InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market
2022-11-18 13:00 ET
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market
2022-11-17 12:30 ET
InMed Provides Update on Management Changes
2022-11-16 12:00 ET
InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada ("NSERC") Alliance Grant Funding
2022-11-11 23:51 ET
InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update
2022-11-10 12:30 ET
Registration Now Open For Tribe Public’s Webinar Event "Exploring the Neuroprotective Qualities of Rare Cannabinoids" Featuring InMed’s Management Team On November 17, 2022
2022-10-26 11:30 ET
InMed Pharmaceuticals Supports Epidermolysis Bullosa Awareness Week
2022-09-23 16:29 ET
InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update
2022-09-19 22:00 ET
InMed Pharmaceuticals to Report Full Year Fiscal 2022 Financial Results and Business Update on September 23, 2022
2022-09-09 21:00 ET
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market
2022-09-08 18:08 ET
InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business
2022-08-23 21:00 ET
InMed Announces Share Consolidation to Meet Nasdaq Listing Criteria
2022-08-09 11:30 ET
InMed Announces Changes to its Board of Directors
2022-07-25 11:30 ET
InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa
2022-07-18 11:30 ET
InMed Announces Appointment of Chief Operating Officer
2022-07-13 03:33 ET
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance
2022-06-14 11:30 ET
InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions
2022-06-09 11:30 ET
InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector
2022-06-06 22:49 ET
InMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules
2022-06-02 12:00 ET
InMed Pharmaceuticals Announces $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules
2022-05-13 11:30 ET
InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update
2022-05-05 11:30 ET
InMed to Supply Rare Cannabinoids to Radicle Science’s “Radicle Energy Study” to Assess the Health Effects of THCV
2022-05-03 16:00 ET
InMed Pharmaceuticals (INM): Notable Launches of High-Value Rare Cannabinoids
2022-04-28 11:30 ET
InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Cannabinoid Research Expert
2022-04-21 11:30 ET
InMed Commercializes Cannabidivarin (CBDV), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector
2022-04-19 11:30 ET
InMed to Participate in Upcoming Investor Conferences in April and May 2022
2022-03-17 11:30 ET
InMed Announces Management Changes
2022-03-08 12:30 ET
InMed to Present at the 34th Annual Roth Conference
2022-02-16 12:30 ET
InMed Pharmaceuticals (INM): Generating Commercial Sales of CBC and CBT
2022-02-15 12:30 ET
InMed Pharmaceuticals Strengthens its Commercial Leadership Team with the Appointment of Vice President of Sales and Marketing for BayMedica
2022-02-15 00:34 ET
InMed Pharmaceuticals Reports Second Quarter Fiscal 2022 Financial Results and Provides Business Update
2022-02-10 12:30 ET
InMed Pharmaceuticals to Report Second Quarter Fiscal 2022 Financial Results and Business Update on February 15, 2022
2022-01-19 12:30 ET
InMed Launches Cannabicitran (CBT), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector
2022-01-05 12:30 ET
InMed Issues Annual Letter to Shareholders Highlighting Key Accomplishments from 2021 and Providing 2022 Outlook
2021-12-30 12:30 ET
Registration Now Open For Tribe Public’s Webinar Event "Addressing The Increasing Demand For Rare Cannabinoids" Featuring InMed’s Management Team On January 6, 2022
2021-12-20 12:30 ET
InMed Pharmaceuticals Announces Publication of Peer-Reviewed Article on the Use of CBN as a Potential Treatment for Glaucoma
2021-12-18 00:57 ET
InMed Announces Results of 2021 Annual General Meeting
2021-11-23 12:30 ET
InMed Pharmaceuticals to Participate in Cowen’s 4th Annual Cannabis Conference
2021-11-17 13:25 ET
InMed Pharmaceuticals (INM): Progress Across the Business
2021-11-10 12:30 ET
InMed Pharmaceuticals Reports First Quarter Fiscal 2022 Financial Results and Provides Business Update
2021-11-03 11:30 ET
InMed Pharmaceuticals Files PCT Patent Application for Treating Neurodegenerative Disease Using a Rare Cannabinoid
2021-10-13 20:30 ET
InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids
2021-09-30 11:30 ET
InMed Pharmaceuticals Announces Commencement of Phase 2 Clinical Trial Investigating Cannabinol (CBN), a Rare Cannabinoid, in the Treatment of Epidermolysis Bullosa
2021-09-24 11:30 ET
InMed Pharmaceuticals Reports Full Year Fiscal 2021 Financial Results and Provides Business Update
2021-09-20 11:50 ET
InMed Pharmaceuticals (INM): Acquiring BayMedica
2021-09-17 17:14 ET
InMed Pharmaceuticals to Report Full Year Fiscal 2021 Financial Results and Business Update on September 24, 2021
2021-09-17 11:30 ET
InMed Pharmaceuticals and BayMedica Participating in Tribe Public’s Webinar "Accelerating The Commercialization of Rare Cannabinoids"
2021-09-13 11:30 ET
InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cannabinoids
2021-09-09 23:18 ET
InMed Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
2021-09-07 20:04 ET
InMed Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com September 8th
2021-08-12 16:00 ET
InMed Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference
2021-06-29 11:00 ET
InMed Pharmaceuticals Announces $12 Million Private Placement Priced At-the-Market under Nasdaq Rules
2021-06-29 11:00 ET
InMed Pharmaceuticals Signs Non-binding Letter of Intent to Acquire BayMedica, a Commercial Manufacturer of Rare Cannabinoids
2021-06-22 16:29 ET
InMed Pharmaceuticals to Webcast Live at Life Sciences Investor Forum June 24th
2021-06-17 11:30 ET
InMed Pharmaceuticals Increases Cannabinoid Yield to 5 g/L with IntegraSyn™ in Advance of Commercial Scale Production
2021-06-09 15:30 ET
InMed Pharmaceuticals to Present at the 2021 BIO Digital Conference
2021-05-13 11:30 ET
InMed Pharmaceuticals Reports Third Quarter Fiscal 2021 Financial Results
2021-05-06 11:30 ET
InMed Pharmaceuticals to Report Third Quarter Fiscal 2021 Financial Results
2021-05-04 11:30 ET
InMed to Present at Canaccord Genuity’s 5th Annual Global Cannabis Conference on May 11th, 2021
2021-04-28 11:30 ET
InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa
2021-04-27 11:30 ET
InMed Pharmaceuticals Announces Voluntary Delisting from TSX
2021-04-26 11:30 ET
InMed Pharmaceuticals Achieves 2g/L Cannabinoid Yield with IntegraSyn™
2021-03-03 23:00 ET
InMed to Present at Virtual Conferences in March 2021
2021-02-16 12:30 ET
InMed Announces Closing of US$4.5 Million Private Placement
2021-02-11 12:30 ET
InMed Pharmaceuticals Reports Second Quarter Fiscal 2021 Financial Results
2021-02-06 02:00 ET
InMed Pharmaceuticals to Report Second Quarter Fiscal 2021 Financial Results
2021-02-05 14:34 ET
InMed Announces US$4.5 Million Private Placement
2021-01-19 19:00 ET
InMed Pharmaceuticals to Participate in 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe
2021-01-08 12:30 ET
InMed Announces Results of Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
2021-01-05 21:52 ET
InMed to Participate at Virtual Conferences in January 2021
2020-12-03 12:30 ET
InMed Licenses MiDROPS® Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoids
2020-11-25 12:30 ET
InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
2020-11-25 01:00 ET
InMed Announces Election of Directors
2020-11-18 12:30 ET
InMed Pharmaceuticals and BayMedica Announce Collaboration for Manufacturing and Testing of Novel Cannabinoid Therapeutics
2020-11-16 16:42 ET
InMed Pharmaceuticals Announces the Closing of US$8 Million Public Offering
2020-11-13 12:30 ET
InMed Pharmaceuticals Reports First Quarter Fiscal 2021 IFRS Financial Results
2020-11-12 14:10 ET
InMed Announces Pricing of US$8M Public Offering and Listing on the Nasdaq Capital Market Under the Symbol "INM"

SEC forms

Show financial reports only

SEC form 10
2024-02-13 00:00 ET
InMed Pharmaceuticals Inc. reported for 2023 q4
SEC form 10
2023-11-14 00:00 ET
InMed Pharmaceuticals Inc. reported for 2023 q3
SEC form 10
2023-11-13 17:34 ET
InMed Pharmaceuticals Inc. reported for 2023 q3
SEC form 10
2023-09-29 11:43 ET
InMed Pharmaceuticals Inc. reported for 2023 q2
SEC form 10
2023-09-29 00:00 ET
InMed Pharmaceuticals Inc. reported for 2023 q2
SEC form 6
2023-09-07 18:35 ET
InMed Pharmaceuticals Inc. published news for 2023 q2
SEC form 6
2023-07-24 16:26 ET
InMed Pharmaceuticals Inc. published news for 2023 q2
SEC form 6
2023-07-20 14:18 ET
InMed Pharmaceuticals Inc. published news for 2023 q2
SEC form 6
2023-06-22 16:28 ET
InMed Pharmaceuticals Inc. published news for 2023 q1
SEC form 6
2023-06-01 13:27 ET
InMed Pharmaceuticals Inc. published news for 2023 q1
SEC form 6
2023-05-25 12:35 ET
InMed Pharmaceuticals Inc. published news for 2023 q1
SEC form 6
2023-05-19 13:41 ET
InMed Pharmaceuticals Inc. published news for 2023 q1
SEC form 6
2023-05-16 13:47 ET
InMed Pharmaceuticals Inc. reported for 2023 q1
SEC form 10
2023-05-15 11:46 ET
InMed Pharmaceuticals Inc. reported for 2023 q1
SEC form 10
2023-05-15 00:00 ET
InMed Pharmaceuticals Inc. reported for 2023 q1
SEC form 6
2023-03-28 13:40 ET
InMed Pharmaceuticals Inc. published news for 2022 q4
SEC form 6
2023-03-14 12:58 ET
InMed Pharmaceuticals Inc. published news for 2022 q4
SEC form 6
2023-03-07 16:00 ET
InMed Pharmaceuticals Inc. published news for 2022 q4
SEC form 6
2023-02-17 20:46 ET
InMed Pharmaceuticals Inc. reported for 2022 q4
SEC form 10
2023-02-17 16:06 ET
InMed Pharmaceuticals Inc. reported for 2022 q4
SEC form 10
2023-02-17 00:00 ET
InMed Pharmaceuticals Inc. reported for 2022 q4
SEC form 6
2023-02-09 21:40 ET
InMed Pharmaceuticals Inc. published news for 2022 q4
SEC form 6
2023-01-10 13:00 ET
InMed Pharmaceuticals Inc. published news for 2022 q4
SEC form 6
2022-12-16 17:30 ET
InMed Pharmaceuticals Inc. published news for 2022 q3
SEC form 6
2022-12-15 19:10 ET
InMed Pharmaceuticals Inc. published news for 2022 q3
SEC form 6
2022-12-13 16:01 ET
InMed Pharmaceuticals Inc. published news for 2022 q3
SEC form 6
2022-12-13 15:47 ET
InMed Pharmaceuticals Inc. published news for 2022 q3
SEC form 6
2022-12-12 20:14 ET
InMed Pharmaceuticals Inc. published news for 2022 q3
SEC form 6
2022-11-29 18:58 ET
InMed Pharmaceuticals Inc. published news for 2022 q3
SEC form 6
2022-11-21 19:02 ET
InMed Pharmaceuticals Inc. published news for 2022 q3
SEC form 6
2022-11-17 16:10 ET
InMed Pharmaceuticals Inc. published news for 2022 q3
SEC form 6
2022-11-17 10:24 ET
InMed Pharmaceuticals Inc. published news for 2022 q3
SEC form 6
2022-11-14 17:44 ET
InMed Pharmaceuticals Inc. reported for 2022 q3
SEC form 10
2022-11-14 06:22 ET
InMed Pharmaceuticals Inc. reported for 2022 q3
SEC form 10
2022-11-14 00:00 ET
InMed Pharmaceuticals Inc. reported for 2022 q3
SEC form 6
2022-10-28 15:11 ET
InMed Pharmaceuticals Inc. published news for 2022 q3
SEC form 6
2022-10-26 16:09 ET
InMed Pharmaceuticals Inc. published news for 2022 q3
SEC form 6
2022-09-29 13:52 ET
InMed Pharmaceuticals Inc. published news for 2022 q2
SEC form 6
2022-09-28 13:34 ET
InMed Pharmaceuticals Inc. published news for 2022 q2
SEC form 6
2022-09-23 16:53 ET
InMed Pharmaceuticals Inc. published news for 2022 q2
SEC form 10
2022-09-23 15:33 ET
InMed Pharmaceuticals Inc. reported for 2022 q2
SEC form 10
2022-09-23 00:00 ET
InMed Pharmaceuticals Inc. reported for 2022 q2
SEC form 6
2022-09-20 13:13 ET
InMed Pharmaceuticals Inc. published news for 2022 q2
SEC form 6
2022-09-13 21:59 ET
InMed Pharmaceuticals Inc. published news for 2022 q2
SEC form 6
2022-09-08 16:02 ET
InMed Pharmaceuticals Inc. published news for 2022 q2
SEC form 6
2022-08-26 17:30 ET
InMed Pharmaceuticals Inc. published news for 2022 q2
SEC form 6
2022-08-10 20:14 ET
InMed Pharmaceuticals Inc. published news for 2022 q2
SEC form 6
2022-08-10 20:12 ET
InMed Pharmaceuticals Inc. published news for 2022 q2
SEC form 6
2022-07-26 13:32 ET
InMed Pharmaceuticals Inc. published news for 2022 q2
SEC form 6
2022-07-19 19:43 ET
InMed Pharmaceuticals Inc. published news for 2022 q2
SEC form 6
2022-07-15 20:28 ET
InMed Pharmaceuticals Inc. published news for 2022 q2
SEC form 6
2022-06-23 19:52 ET
InMed Pharmaceuticals Inc. published news for 2022 q1
SEC form 6
2022-06-21 18:45 ET
InMed Pharmaceuticals Inc. published news for 2022 q1
SEC form 6
2022-06-15 18:04 ET
InMed Pharmaceuticals Inc. published news for 2022 q1
SEC form 6
2022-06-10 16:36 ET
InMed Pharmaceuticals Inc. published news for 2022 q1
SEC form 6
2022-06-06 21:47 ET
InMed Pharmaceuticals Inc. published news for 2022 q1
SEC form 6
2022-06-03 21:51 ET
InMed Pharmaceuticals Inc. published news for 2022 q1
SEC form 6
2022-05-19 16:22 ET
InMed Pharmaceuticals Inc. published news for 2022 q1
SEC form 6
2022-05-18 13:34 ET
InMed Pharmaceuticals Inc. published news for 2022 q1
SEC form 10
2022-05-13 07:30 ET
InMed Pharmaceuticals Inc. reported for 2022 q1
SEC form 10
2022-05-13 00:00 ET
InMed Pharmaceuticals Inc. reported for 2022 q1
SEC form 6
2022-05-06 14:50 ET
InMed Pharmaceuticals Inc. published news for 2022 q1
SEC form 6
2022-04-28 14:35 ET
InMed Pharmaceuticals Inc. published news for 2022 q1
SEC form 6
2022-04-21 14:46 ET
InMed Pharmaceuticals Inc. published news for 2022 q1
SEC form 6
2022-04-19 18:55 ET
InMed Pharmaceuticals Inc. published news for 2022 q1
SEC form 6
2022-04-08 15:07 ET
InMed Pharmaceuticals Inc. published news for 2022 q1
SEC form 6
2022-04-07 16:47 ET
InMed Pharmaceuticals Inc. published news for 2022 q1
SEC form 6
2022-03-22 06:05 ET
InMed Pharmaceuticals Inc. published news for 2021 q4
SEC form 6
2022-03-18 13:02 ET
InMed Pharmaceuticals Inc. published news for 2021 q4
SEC form 6
2022-03-09 12:58 ET
InMed Pharmaceuticals Inc. published news for 2021 q4
SEC form 6
2022-02-23 13:10 ET
InMed Pharmaceuticals Inc. published news for 2021 q4
SEC form 6
2022-02-22 20:15 ET
InMed Pharmaceuticals Inc. published news for 2021 q4
SEC form 6
2022-02-15 13:17 ET
InMed Pharmaceuticals Inc. published news for 2021 q4
SEC form 6
2022-02-14 21:16 ET
InMed Pharmaceuticals Inc. published news for 2021 q4
SEC form 10
2022-02-14 16:59 ET
InMed Pharmaceuticals Inc. published news for 2021 q4
SEC form 10
2022-02-14 00:00 ET
InMed Pharmaceuticals Inc. published news for 2021 q4
SEC form 6
2022-02-10 12:34 ET
InMed Pharmaceuticals Inc. published news for 2021 q4
SEC form 6
2022-01-19 16:09 ET
InMed Pharmaceuticals Inc. published news for 2021 q4
SEC form 6
2022-01-05 14:22 ET
InMed Pharmaceuticals Inc. published news for 2021 q4
SEC form 6
2021-12-22 06:03 ET
InMed Pharmaceuticals Inc. published news for 2021 q3
SEC form 6
2021-12-17 19:29 ET
InMed Pharmaceuticals Inc. published news for 2021 q3
SEC form 6
2021-11-23 13:32 ET
InMed Pharmaceuticals Inc. published news for 2021 q3
SEC form 6
2021-11-16 17:29 ET
InMed Pharmaceuticals Inc. published news for 2021 q3
SEC form 6
2021-11-10 13:08 ET
InMed Pharmaceuticals Inc. published news for 2021 q3
SEC form 10
2021-11-10 07:31 ET
InMed Pharmaceuticals Inc. published news for 2021 q3
SEC form 10
2021-11-10 00:00 ET
InMed Pharmaceuticals Inc. published news for 2021 q3
SEC form 6
2021-11-09 15:50 ET
InMed Pharmaceuticals Inc. published news for 2021 q3
SEC form 6
2021-11-03 14:00 ET
InMed Pharmaceuticals Inc. published news for 2021 q3
SEC form 6
2021-10-28 15:07 ET
InMed Pharmaceuticals Inc. published news for 2021 q3
SEC form 6
2021-10-28 13:29 ET
InMed Pharmaceuticals Inc. published news for 2021 q3
SEC form 6
2021-10-13 17:00 ET
InMed Pharmaceuticals Inc. published news for 2021 q3
SEC form 6
2021-10-01 16:46 ET
InMed Pharmaceuticals Inc. published news for 2021 q3
SEC form 6
2021-09-30 13:30 ET
InMed Pharmaceuticals Inc. published news for 2021 q2
SEC form 6
2021-09-24 16:07 ET
InMed Pharmaceuticals Inc. published news for 2021 q2
SEC form 10
2021-09-24 07:31 ET
InMed Pharmaceuticals Inc. published news for 2021 q2
SEC form 10
2021-09-24 00:00 ET
InMed Pharmaceuticals Inc. published news for 2021 q2
SEC form 6
2021-09-20 13:09 ET
InMed Pharmaceuticals Inc. published news for 2021 q2
SEC form 6
2021-09-13 08:00 ET
InMed Pharmaceuticals Inc. published news for 2021 q2
SEC form 6
2021-09-10 06:13 ET
InMed Pharmaceuticals Inc. published news for 2021 q2
SEC form 6
2021-09-08 06:04 ET
InMed Pharmaceuticals Inc. published news for 2021 q2
SEC form 6
2021-08-12 15:33 ET
InMed Pharmaceuticals Inc. published news for 2021 q2
SEC form 6
2021-07-02 16:27 ET
InMed Pharmaceuticals Inc. published news for 2021 q2
SEC form 6
2021-06-29 18:08 ET
InMed Pharmaceuticals Inc. published news for 2021 q1
SEC form 6
2021-06-29 15:12 ET
InMed Pharmaceuticals Inc. published news for 2021 q1
SEC form 6
2021-06-22 19:20 ET
InMed Pharmaceuticals Inc. published news for 2021 q1
SEC form 6
2021-06-17 13:19 ET
InMed Pharmaceuticals Inc. published news for 2021 q1
SEC form 6
2021-06-09 11:30 ET
InMed Pharmaceuticals Inc. published news for 2021 q1
SEC form 6
2021-05-13 16:23 ET
InMed Pharmaceuticals Inc. published news for 2021 q1
SEC form 10
2021-05-13 06:01 ET
InMed Pharmaceuticals Inc. published news for 2021 q1
SEC form 10
2021-05-13 00:00 ET
InMed Pharmaceuticals Inc. published news for 2021 q1
SEC form 6
2021-05-06 07:30 ET
InMed Pharmaceuticals Inc. published news for 2021 q1
SEC form 6
2021-05-04 11:10 ET
InMed Pharmaceuticals Inc. published news for 2021 q1
SEC form 6
2021-04-28 13:31 ET
InMed Pharmaceuticals Inc. published news for 2021 q1
SEC form 6
2021-04-28 11:43 ET
InMed Pharmaceuticals Inc. published news for 2021 q1
SEC form 6
2021-04-27 16:22 ET
InMed Pharmaceuticals Inc. published news for 2021 q1
SEC form 6
2021-03-04 15:21 ET
InMed Pharmaceuticals Inc. published news for 2020 q4
SEC form 6
2021-03-02 18:35 ET
InMed Pharmaceuticals Inc. published news for 2020 q4
SEC form 6
2021-02-16 06:12 ET
InMed Pharmaceuticals Inc. published news for 2020 q4
SEC form 6
2021-02-12 12:35 ET
InMed Pharmaceuticals Inc. published news for 2020 q4
SEC form 10
2021-02-11 07:01 ET
InMed Pharmaceuticals Inc. published news for 2020 q4
SEC form 6
2021-02-05 17:28 ET
InMed Pharmaceuticals Inc. published news for 2020 q4
SEC form 6
2021-01-20 15:43 ET
InMed Pharmaceuticals Inc. published news for 2020 q4
SEC form 6
2021-01-19 14:42 ET
InMed Pharmaceuticals Inc. published news for 2020 q4
SEC form 6
2021-01-11 06:03 ET
InMed Pharmaceuticals Inc. published news for 2020 q4
SEC form 6
2021-01-08 10:53 ET
InMed Pharmaceuticals Inc. published news for 2020 q4
SEC form 6
2021-01-05 19:53 ET
InMed Pharmaceuticals Inc. published news for 2020 q4
SEC form 10
2020-12-16 21:18 ET
InMed Pharmaceuticals Inc. published news for 2020 q3
SEC form 6
2020-12-04 13:48 ET
InMed Pharmaceuticals Inc. published news for 2020 q3
SEC form 6
2020-12-03 12:59 ET
InMed Pharmaceuticals Inc. published news for 2020 q3
SEC form 6
2020-11-25 10:47 ET
InMed Pharmaceuticals Inc. published news for 2020 q3
SEC form 6
2020-11-24 20:00 ET
InMed Pharmaceuticals Inc. published news for 2020 q3
SEC form 6
2020-11-18 12:31 ET
InMed Pharmaceuticals Inc. published news for 2020 q3
SEC form 6
2020-11-16 15:00 ET
InMed Pharmaceuticals Inc. published news for 2020 q3
SEC form 6
2020-11-13 13:19 ET
InMed Pharmaceuticals Inc. published news for 2020 q3
SEC form 6
2020-11-12 14:22 ET
InMed Pharmaceuticals Inc. published news for 2020 q3
SEC form 6
2020-11-12 14:18 ET
InMed Pharmaceuticals Inc. published news for 2020 q3
SEC form 6
2020-11-12 14:14 ET
InMed Pharmaceuticals Inc. published news for 2020 q3
SEC form 6
2020-11-12 14:06 ET
InMed Pharmaceuticals Inc. published news for 2020 q3
SEC form 6
2020-11-12 13:56 ET
InMed Pharmaceuticals Inc. published news for 2020 q3
SEC form 6
2020-11-12 13:44 ET
InMed Pharmaceuticals Inc. published news for 2020 q3
SEC form 6
2020-11-12 13:41 ET
InMed Pharmaceuticals Inc. published news for 2020 q3
SEC form 6
2020-11-12 13:36 ET
InMed Pharmaceuticals Inc. published news for 2020 q3
SEC form 6
2020-11-12 12:13 ET
InMed Pharmaceuticals Inc. published news for 2020 q3
SEC form 6
2020-11-12 10:15 ET
InMed Pharmaceuticals Inc. published news for 2020 q3

SEDAR forms

Show financial reports only

SEDAR form
2023-05-15
INM published news for 2023 q2
SEDAR form
2023-02-17
INM published news for 2023 q1
SEDAR form
2022-11-14
INM published news for 2022 q4
SEDAR form
2022-09-23
INM published news for 2022 q3
SEDAR form
2022-09-23
INM published news for 2022 q3
SEDAR form
2022-09-23
INM published news for 2022 q3
SEDAR form
2022-05-13
INM published news for 2022 q2
SEDAR form
2022-02-14
INM published news for 2022 q1
SEDAR form
2021-11-10
INM published news for 2021 q4
SEDAR form
2021-09-29
INM published news for 2021 q3
SEDAR form
2021-09-29
INM published news for 2021 q3
SEDAR form
2021-09-29
INM published news for 2021 q3
SEDAR form
2021-05-13
INM published news for 2021 q2
SEDAR form
2021-02-11
INM published news for 2021 q1
SEDAR form
2020-12-17
INM published news for 2020 q4
SEDAR form
2020-11-13
INM published news for 2020 q4
SEDAR form
2020-09-08
INM published news for 2020 q3
SEDAR form
2020-09-08
INM published news for 2020 q3
SEDAR form
2020-09-08
INM published news for 2020 q3
SEDAR form
2020-05-14
INM published news for 2020 q2
SEDAR form
2020-02-14
INM published news for 2020 q1
SEDAR form
2020-02-13
INM published news for 2020 q1